Tranexamic Acid and its effect on TURP operation

Evaluation of intravenous Tranexamic acid effect on blood loss during and post transurethral resection of prostate (TURP) surgery: A Randomized Placebo-controlled Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015030111822N5

Enrollment

Registered

2017-06-06

Start date

2014-09-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign hypertrophy of prostate. Hypertrophy (benign) of prostate

Interventions

Intervention 1: as starting the serum therapy for case group, the 500cc Tranexamic acid in 500cc ringer serum with 1mg/ml concentration and maximum flow 100mg/min. Intervention 2: transfusion of 500cc

Prevention

Placebo

as starting the serum therapy for case group, the 500cc Tranexamic acid in 500cc ringer serum with 1mg/ml concentration and maximum flow 100mg/min

transfusion of 500cc ringer serum solely

Eligibility

Sex/Gender

Male

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with BPH; that are 50-80 years old. their prostate gland weight was measured by sonography. measuring of Hb, Hct before the surgery. ASA=II. Exclusion criteria: patient disagreement.renal dysfunction .color vision dysfunction .coagulopathy. IHD or arrhythmia .anticoagulant consumption, CVA. Hx of tranexamic acid allergy. Hx of PTE or DVT.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hct. Timepoint: before and 6hr after surgery. Method of measurement: automatic analysor.(cell count).;Hb. Timepoint: before and 6hr after surgery. Method of measurement: automatic analysor.(cell count).;Prostate weight. Timepoint: before the surgery. Method of measurement: by sonography in mg.;Duration of the surgery. Timepoint: after the surgery. Method of measurement: as soon as entering to urinary urethral until foley catheter fixation.;Sergeon satisfaction. Timepoint: after the surgery. Method of measurement: surgeon opinion.;Transfusion. Timepoint: after the surgery. Method of measurement: amount of unit packed cell.;Serum volume during the surgery. Timepoint: after the surgery. Method of measurement: intake serum volume in cc.	—

Measure

Time frame

Hct. Timepoint: before and 6hr after surgery. Method of measurement: automatic analysor.(cell count).;Hb. Timepoint: before and 6hr after surgery. Method of measurement: automatic analysor.(cell count).;Prostate weight. Timepoint: before the surgery. Method of measurement: by sonography in mg.;Duration of the surgery. Timepoint: after the surgery. Method of measurement: as soon as entering to urinary urethral until foley catheter fixation.;Sergeon satisfaction. Timepoint: after the surgery. Method of measurement: surgeon opinion.;Transfusion. Timepoint: after the surgery. Method of measurement: amount of unit packed cell.;Serum volume during the surgery. Timepoint: after the surgery. Method of measurement: intake serum volume in cc.

—

Secondary

Measure	Time frame
Nausea. Timepoint: 6 hr after surgery. Method of measurement: Ask the patient.;Seizure. Timepoint: 6 hr after surgery. Method of measurement: Ask the patient.;Vomiting. Timepoint: 6 hr after surgery. Method of measurement: Ask the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehrooz Karkhanei

Hamadan University of Medical sciences

karkhanei@umsha.ac.ir+98 81 3838 0574

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026